Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- APDD to Promote Clinical Trials
February 20, 2006
- ＜Symposium＞ "Tamiflu Should Not Be Used": Medwatcher Japan
February 20, 2006
- REGULATORY NEWS IN BRIEF
February 20, 2006
- 2006 Pollen Websites
February 13, 2006
- Nationwide Delivery of Generics Is Possible: Mr Nakagawa
February 13, 2006
- New Prescription Form Taking Shape
February 13, 2006
- Japanese GE Market "a Big Opportunity": Dr Rummelt of Sandoz
February 13, 2006
- Pfizer Receives FDA Approval for New Anticancer Agent
February 13, 2006
- New Guidance Issued on On-site GCP Compliance Inspections
February 13, 2006
- Relenza Recommended for Approval for Infants: CDFS
February 13, 2006
- Meeting of Pref. Officials Responsible for HLW
February 13, 2006
- REGULATORY NEW IN BRIEF
February 13, 2006
- Teikoku Seiyaku, Altea Therapeutics Announce License Agreement
February 13, 2006
- Astellas Licenses Prostate Cancer Treatment from Ferring
February 13, 2006
- 3 Switch-OTC Drugs Recommended for Approval
February 13, 2006
- R&D NEW IN BRIEF
February 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
February 13, 2006
- National Burden Rate to Decline to 37.7% in FY2006
February 13, 2006
- Mochida: Moving Ahead with Priority on Profits, Forward-looking Investment
February 13, 2006
- Quintiles Expanding ECG Analysis Service in India
February 13, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…